共 50 条
- [1] Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant MelanomaCLINICAL CANCER RESEARCH, 2017, 23 (18) : 5339 - 5348Delord, Jean-PierreRobert, CarolineNyakas, MartaMcArthur, Grant A.Kudchakar, RaginiMahipal, AmitYamada, YasuhideSullivan, RyanArance, AnaKefford, Richard F.Carlino, Matteo S.Hidalgo, ManuelGomez-Roca, CarlosMichel, DanielaSeroutou, AbdelkaderAslanis, VassiliosCaponigro, GiordanoStuart, Darrin D.Moutouh-de Parseval, LaureDemuth, TimDummer, Reinhard
- [2] Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Kefford, RichardMiller, Wilson H.Tan, Daniel Shao-WengSullivan, Ryan J.Long, GeorginaDienstmann, RodrigoTai, Wai Meng DavidFlaherty, KeithStutvoet, SimoneSchumacher, Karl MariaWandel, SimonDe Parseval, Laure A.Tabernero, Josep
- [3] Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary resultsJournal of Translational Medicine, 12 (Suppl 1)Richard KeffordRyan J SullivanWilson H MillerElena M ElezDaniel TanKevin B KimGeorgina V LongKeith T FlahertyDavid TaiSimone StutvoetHeiko MaackeMatt WhileyLaure Moutouh-de ParsevalJosep Tabernero
- [4] PHASE IB/II STUDY OF LEE011 (CDK4/6 INHIBITOR) AND LGX818 (BRAF INHIBITOR) IN BRAF-MUTANT MELANOMAANNALS OF ONCOLOGY, 2014, 25Taylor, M.Sosman, J.Gonzalez, R.Carlino, M. S.Kittaneh, M.Lolkema, M. P.Miller, W.Marino, A.Zhang, V.Bhansali, S. G.Parasuraman, S.Postow, M. A.
- [5] Final biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancerCANCER RESEARCH, 2015, 75Schellens, Jan H. M.van Geel, RobinBendell, Johanna C.Spreafico, AnnaSchuler, MartinYoshino, TakayukiDelord, Jean-PierreYamada, YasuhideLolkema, Martijn P.Faris, Jason E.Eskens, Ferry A. L. M.Sharma, SunilYaeqer, RonaLenz, Heinz-JosefWainberg, Zev A.Avsar, EminChatterjee, ArkenduJaeger, SavinaDemuth, TimTabemero, Josep
- [6] Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanomaEUROPEAN JOURNAL OF CANCER, 2020, 135 : 31 - 38Si, LuZhang, XiaoshiShin, Sang JoonFan, YunLin, Chia-ChiKim, Tae MinDechaphunkul, AruneeManeechavakajorn, JedzadaWong, Chi SingIlankumaran, PalanichamyLee, Dung-YangGasal, EduardLi, HaifuGuo, Jun
- [7] Five- year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanomaEUROPEAN JOURNAL OF CANCER, 2019, 109 : 61 - 69Robert, CarolineFlaherty, KeithNathan, PaulHersey, PeterGarbe, ClausMilhem, MohammedDemidov, LevMohr, PeterHassel, Jessica C.Rutkowski, PiotrDummer, ReinhardUtikal, JochenKiecker, FelixLarkin, JamesD'Amelio, Anthony, Jr.Mookerjee, BijoyeshSchadendorf, Dirk
- [8] A single arm, open label, phase II, multicenter study to assess the detection of the BRAF V600 mutation on cfDNA from plasma in patients with advanced melanomaANNALS OF ONCOLOGY, 2019, 30 : 544 - 544Rutkowski, P.Pauwels, P.Kerger, J.Jacobs, B.Maertens, G. G.Gadeyne, V.Liebert, S.Neyns, B.
- [9] A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanomaCANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (01) : 103 - 111Grippo, J. F.Zhang, W.Heinzmann, D.Yang, K. H.Wong, J.Joe, A. K.Munster, P.Sarapa, N.Daud, A.
- [10] Chinese subgroup results from an open-label, phase IIa study of dabrafenib plus trametinib in Asian patients with advanced BRAF V600-mutant melanoma (NCT02083354)ANNALS OF ONCOLOGY, 2020, 31 : S749 - S749Mao, L.Wen, X.Xu, Y.Si, L.Zhang, X.Fan, Y.Guo, J.